Safety monitoring report for COVID-19 mRNA second boosters in adults aged 50+

This is a safety monitoring report from the United States, describing surveillance activities for COVID-19 mRNA vaccine second booster doses. The population of interest is adults aged 50 years and older. The report does not specify a comparator group, primary outcome, or sample size. No main results, adverse event data, serious adverse event rates, or tolerability findings are provided. The follow-up duration is also not reported. The report lists no specific safety findings, adverse events, or discontinuation rates. No tolerability information is available. Key limitations include the absence of reported data, outcomes, and results, making it impossible to assess safety signals. The practice relevance is not reported, and this document should be interpreted only as a notice of surveillance activity, not as evidence of safety or risk.